首页> 外文期刊>Poultry Science >Development of an effective contemporary trivalent avian influenza vaccine against circulating H5N1, H5N8, and H9N2 in Egypt
【24h】

Development of an effective contemporary trivalent avian influenza vaccine against circulating H5N1, H5N8, and H9N2 in Egypt

机译:开发埃及循环H5N1,H5N8和H9N2循环H5N1,H5N8和H9N2的有效当代三价禽流感疫苗

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Low pathogenicity avian influenza (LPAI) H9N2, highly pathogenic avian influenza (HPAI) H5N1, and H5N8 circulate in Egyptian poultry and cause veterinary and public health burdens. In response, AIV vaccines are commonly used. The main objective of this study was to develop a broad, cross-protective, trivalent vaccine based on circulating AIVs in Egypt. We generated highly replicating avirulent AIVs, H5N1, and H5N8, to be used in combination with H9N2 strain for the generation of an inactivated vaccine. Immunogenicity and protective efficacy of this vaccine were tested. Results showed that a single immunization dose enhanced humoral immune responses giving full protection against challenges with LPAI H9N2, HPAI H5N1, and H5N8 viruses. This efficacious vaccine will reduce the cost of vaccination for poultry growers and is expected to be effective in the field as it is based on contemporary viruses currently in circulation among Egyptian poultry.
机译:低致病性禽流感(LPAI)H9N2,高度致病性禽流感(HPAI)H5N1和H5N8在埃及家禽中循环,并导致兽医和公共卫生负担。 作为响应,通常使用AIV疫苗。 本研究的主要目的是基于埃及的循环AIV开发一种广泛的交叉保护性的三价疫苗。 我们产生高度复制的无毒AIV,H5N1和H5N8,以与H9N2菌株组合使用以产生灭活的疫苗。 测试该疫苗的免疫原性和保护性疗效。 结果表明,单一免疫剂量增强了体液免疫应答,充分保护LPAI H9N2,HPAI H5N1和H5N8病毒。 这种有效的疫苗将降低家禽种植者的疫苗接种成本,预计将在现场有效,因为它基于目前埃及家禽之间流通的当代病毒。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号